 | • レポートコード：MRC2108A256 • 出版社/出版日：Mordor Intelligence / 2021年7月 • レポート形態：英文、PDF、68ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥481,000 (USD3,250) | ▷ お問い合わせ |
| Team User | ￥555,000 (USD3,750) | ▷ お問い合わせ |
| Corporate License | ￥962,000 (USD6,500) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社は、体外診断のカナダ市場規模が、2021年から2026年の間に年平均5.2％成長すると予測しています。本調査レポートは、カナダの体外診断市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、検査タイプ別分析、製品別分析、有用性別分析、用途別分析、エンドユーザー別分析、競争状況、市場機会/将来の見通しなどを掲載しています。 |
The Canadian in-vitro diagnostics market is expected to register a CAGR of 5.2% over the forecast period.
The emergence of the SARS-CoV-2 virus has increased lab testing demands to keep pace with suspected cases of COVID-19. Thus, the recent outbreak of COVID-19 is expected to positively impact the in-vitro diagnostics industry, as it involves the testing of various biological samples. In February 2021, Thermo Fisher Scientific received Health Canada authorization for its, Applied Biosystems TaqPath COVID-19 HT Kit, to give a significant boost to laboratories’ COVID-19 testing capabilities. All these developments indicate that the COVID-19 has a positive impact on market growth.
The factors that are responsible for the growth of this market include the increasing use of Point-of-Care (POC) diagnostics, advanced technologies, and increasing awareness and acceptance of personalized medicine and companion diagnostics.
In-Vitro Diagnostics are extremely valuable for disease prevention, detection, and management. They can influence almost two-thirds of clinical decision-making while accounting for just 2% of healthcare spending. Owing to the high burden of various diseases in this region the demand of Point-of-Care diagnostics is increasing . As per the Canadian Cancer Society, in 2020, cancer is the leading cause of death in Canada and is responsible for 30% of all deaths. According to the data published by Globocan 2020, it was estimated that in 2020, approximately 2,74,364 Canadians was diagnosed with cancer. About 86,684 Canadians deaths were reported from cancer.
Additionally, according to Statistics Canada, the number of deaths caused by certain infectious and parasitic diseases in 2019 is found to be 4.323 as compared to 4272 cases in 2017, that comprises of both the sexes. Therefore, the rising cases of certain infectious diseases helps in boosting the demand for in-vitro diagnostics to aid in the diagnosis or detection of these disease.
The emerging technological innovations in healthcare, such as bio-sensors, lab-on-a-chip, wearable devices, and POC diagnostics, are increasingly becoming an important part of the healthcare landscape. POC diagnostics are no longer limited to simple tests and can now be used for diagnosing serious conditions. Market players in this region are focusing on the market development strategies such as product development, merger and acquisition, and partnerships. For instance, in June 2020, Roche’s Elecsys Anti-SARS-CoV-2 serology test authorized under Health Canada’s Interim Order making it available to Canadian laboratories, healthcare professionals and patients. Thus, owing to all these market development strategies coupled with growing burden of several diseases in this region, is expected to propel market growth.
Key Market Trends
Reagents are Expected to hold the Significant Market Share in the Product Segment
The reagent segment of the market studied includes chemical, biological, or immunological components, solutions, or preparations intended by the manufacturer to be used during the in-vitro diagnosis process. Reagents are an integral part of in-vitro diagnostics. They are of a wide varied range, for different types of disease diagnosis. With the growing complexity of diseases and demand for early diagnosis, there is increased use of complex reagent combinations in laboratories to diagnose a disease from biological samples. In addition, for the assessment of a patient’s general health by a physician, the major information comes from the information supplied by the diagnostics laboratory, where the importance of diagnostic reagents becomes evident. Many diagnostic companies have an excess of more than 50% of sales from consumables, such as assays and reagents and such agreements guarantee the generation of cyclic revenues associated with the sale of reagents and other consumables.
Furthermore, increasing competition pressures the laboratories to continuously improve quality and provide rapid results, this demand drives the need for reagents that perform multiple functions efficiently. For instance, in May 2021, LaunchWorks, a contract development and manufacturing organization (CDMO) in molecular diagnostics, and Canadienzyme, a Canadian biotech spin-off company entered into a collaboration to produce a new RT-qPCR Master Mix, a RT-qPCR testing reagent. Thus, all these developments are fueling the growth of the segment.
Competitive Landscape
The Canadian in-vitro diagnostics market is moderately competitive and consists of several major players. In terms of market share, a few of the major players currently dominate the market. In addition, the rising need for diagnostics due to the rising prevalence of diseases and the advances in IVD is helping the few other smaller players in entering the market. Some of the major players of the market are Becton Dickinson and Company, BioMerieux, Bio-Rad Laboratories Inc., Danaher Corporation, and Thermo Fisher Scientific, among others.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumption and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Use of Point-of-Care (POC) Diagnostics and Advancements in Technology
4.2.2 Increasing Awareness and Acceptance of Personalized Medicine and Companion Diagnostics
4.3 Market Restraints
4.3.1 Stringent Regulations and Cumbersome Reimbursement Procedures
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Test Type
5.1.1 Clinical Chemistry
5.1.2 Molecular Diagnostics
5.1.3 Hematology
5.1.4 Immuno Diagnostics
5.1.5 Other Tests
5.2 By Product
5.2.1 Instrument
5.2.2 Reagent
5.2.3 Other Products
5.3 By Usability
5.3.1 Disposable IVD Devices
5.3.2 Reusable IVD Devices
5.4 By Application
5.4.1 Infectious Disease
5.4.2 Diabetes
5.4.3 Cancer/Oncology
5.4.4 Cardiology
5.4.5 Autoimmune Disease
5.4.6 Nephrology
5.4.7 Other Applications
5.5 By End Users
5.5.1 Diagnostic Laboratories
5.5.2 Hospitals and Clinics
5.5.3 Other End Users
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Siemens AG
6.1.2 Danaher Corporation
6.1.3 F. Hoffmann-La Roche AG
6.1.4 Becton, Dickinson and Company
6.1.5 Bio-Rad Laboratories Inc.
6.1.6 Abbott Laboratories
6.1.7 Arkray Inc.
6.1.8 Hologic
6.1.9 Thermo Fischer Scientific Inc.
6.1.10 Qiagen N.V.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS